Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume – Here’s What Happened

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw unusually-strong trading volume on Thursday . 1,779,641 shares were traded during mid-day trading, an increase of 244% from the previous session’s volume of 517,172 shares.The stock last traded at $3.5050 and had previously closed at $3.46.

Wall Street Analysts Forecast Growth

IVA has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Truist Financial assumed coverage on Inventiva in a report on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock. Finally, Wall Street Zen cut Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $16.56.

Inventiva Price Performance

The stock’s 50-day simple moving average is $4.78 and its 200 day simple moving average is $5.35.

Inventiva (NASDAQ:IVA) last posted its quarterly earnings data on Sunday, February 15th. The company reported ($0.16) earnings per share for the quarter. The firm had revenue of $0.01 million for the quarter. Equities research analysts predict that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current year.

Institutional Investors Weigh In On Inventiva

A number of hedge funds and other institutional investors have recently bought and sold shares of IVA. Creative Planning acquired a new position in Inventiva in the second quarter worth $32,000. Millennium Management LLC acquired a new stake in shares of Inventiva in the third quarter valued at $649,000. NewEdge Advisors LLC bought a new position in shares of Inventiva in the third quarter valued at about $116,000. UBS Group AG raised its holdings in shares of Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after buying an additional 2,634,580 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new position in Inventiva during the 4th quarter worth about $1,570,000. 19.06% of the stock is owned by institutional investors and hedge funds.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.